bioAffinity Prices $4M Registered Direct Offering at $6.122 with Warrants
BIAF is trading near its 52-week low of $4.56 (8.1% above the low) on light trading volume (0.1× avg).
Summary
bioAffinity priced a $4 million registered direct offering at $6.122 per share with pre-funded warrants and a concurrent private placement of unregistered warrants, extending its cash runway amid a going concern warning. The offering closed on October 9, 2026, and the company suspended its ATM prospectus supplement.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — bioAffinity closed the $4 million registered direct offering on October 9, 2026, and suspended its ATM prospectus supplement.
Key Events · Financing and Capital Events · BIAF
-
New · · SEC 8-K
ATM Prospectus Supplement Suspended
bioAffinity suspended its ATM prospectus supplement.
-
Updated · · SEC 8-K
Registered Direct Offering Priced and Closed
The offering consists of 116,545 shares at $6.122 per share plus pre-funded warrants for up to 536,836 shares at $6.115 per warrant, totaling $3,996,241 in gross proceeds. The offering closed on October 9, 2026.
-
Concurrent Private Placement
Unregistered warrants to purchase up to 980,072 shares at $6.122 per share, exercisable upon stockholder approval for five years, plus 19,602 placement agent warrants.
-
Net Proceeds and Use
Estimated net proceeds of approximately $4 million after fees and expenses, intended for working capital and general corporate purposes.
-
Dilution Impact
Shares outstanding increase from 1,166,625 to 1,283,170 immediately; full exercise of all warrants could add up to 1,536,510 additional shares.
Analysis · BIAF · Industrial Applications And Services
Roughly $4 million in net proceeds is being raised through a registered direct offering of common stock and pre-funded warrants, alongside a concurrent private placement of unregistered warrants. The offering is priced at $6.122 per share, a slight discount to the $6.16 last reported sale price on October 7, 2025, and comes as the company faces a going concern warning and a cash runway that was projected to end in August 2026. The capital extends the runway but adds substantial potential dilution: the 116,545 shares sold immediately increase the share count from 1,166,625 to 1,283,170, and the pre-funded warrants, unregistered warrants, and placement agent warrants could add up to 1,536,510 more shares if fully exercised. The unregistered warrants are exercisable only after stockholder approval, which the company is seeking via a preliminary proxy filed September 29, 2026. The offering closed on October 9, 2026, and the company suspended its ATM prospectus supplement.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $4.93 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8M. The 52-week trading range was $4.56 to $80.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.